To Evaluate the Efficacy and Safety of Levocetirizine Versus Loratadine for Treatment of Seasonal Allergic Rhinitis

UCB

Status and phase: Completed; Phase 3

Conditions: Rhinitis; Seasonal; Allergic

Treatments: Drug: Levocetirizine dihydrochloride

Study type: Interventional

Funder types: Industry

Identifiers

NCT00525278

A00348

Details and patient eligibility

About

To Evaluate the Efficacy and Safety of Levocetirizine Versus Loratadine for Treatment of Seasonal Allergic Rhinitis

Enrollment: 67 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female, 18 to 60 years old, inclusive
• two-year history of allergic rhinitis due to tree, grass or weed pollen
• sufficient histamine-dependent symptoms of rhinitis during the selection week (T5SS ≥ 5)

Exclusion criteria

• An ear, nose or throat (ENT) infection
• asthma requiring daily drug therapy other than ß2 inhaled agonists taken prn
• atopic dermatitis or urticaria requiring an antihistamine or corticosteroid treatment
• an associated ENT disease
• use of decongestants
• nasal or ocular topical treatment

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind